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low ‑intensity treatment (Step 2). This encom‑
passes patients with sporadic asthma and those 
with more frequent symptoms.
Regardless of asthma severity level airway in‑
flammation is always present.7 Currently, regular 
controller treatment is indicated in patients re‑
quiring inhaled reliever therapy more than twice 
per week, or any nocturnal symptoms, or limita‑
tion of activities due to asthma, or risk factors 
for asthma exacerbations.6 The preferred ther‑
apeutic option in this group is the regular use 
of low ‑dose inhaled corticosteroids (ICSs). ICSs 
are the most effective agents for controlling air‑
way inflammation and modifying the course of 
the disease, regardless of its severity.5 Anoth‑
er possibility of low ‑intensity controller treat‑
ment is the use of leukotriene receptor antago‑
nists, which are less effective than ICSs, but may 
be chosen by patients with concerns about side 
effects of ICS treatment.
Introduction The number of patients with asth‑
ma exceeds 300 million globally.1 Asthma consti‑
tutes a significant burden to patients and health 
care systems worldwide. According to Global Bur‑
den of Disease Study data in 2015, 26.2 million 
disability ‑adjusted life years were lost due to 
asthma and as much as 400 000 patients died 
of asthma.2 The data on asthma burden are con‑
cordant with those demonstrating that the goals 
of treatment (including symptom control and 
prevention of exacerbations) are not achieved 
in a significant proportion of patients,3,4 even 
though most patients (50%–75%) have mild 
disease.5 Currently, asthma severity classifica‑
tion is based on the level of treatment intensi‑
ty needed to control the symptoms and should 
be assessed after several months of controller 
treatment (TAbLE 1).6 Mild asthma is defined as 
the disease that is controlled with as ‑needed re‑
liever medication alone (Step 1) or with regular 
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AbsTRACT
Asthma affects about 300 million individuals worldwide. Although most patients have mild disease, 
the majority of them do not have good control and are at risk of exacerbations. Poor compliance with 
regular maintenance treatment is a considerable problem and is believed to be the main reason for poor 
control in asthma. In patients with moderate to severe asthma, maintenance and as ‑needed treatment 
with one inhaler containing an inhaled corticosteroid (ICS) and the long ‑acting inhaled β2 ‑agonist for‑
moterol has been proved effective in reducing the risk of severe exacerbations. Recently, the results of 
2 large double ‑blind randomized trials assessing the use of as ‑needed budesonide/formoterol in patients 
with mild asthma, who had indications for a regular controller treatment, were published. In comparison 
with as ‑needed terbutaline treatment, as ‑needed budesonide/formoterol treatment improved symptom 
control and reduced the risk of exacerbations. In comparison with regular ICS treatment, exacerbation 
rates were similar, but regular treatment schedule was associated with better asthma control (despite 
a higher cumulative ICS dose). The results of these trials have shown that as ‑needed budesonide/
formoterol therapy has acceptable efficacy in mild asthma and may be viewed as a therapeutic option 
for these patients. As ‑needed treatment may be preferred by patients who fear the side effects of ICS 
treatment or by those who experience difficulty in following a fixed ‑dose regimen. Patients with mild 
asthma wishing to achieve optimal asthma control may prefer regular maintenance treatment with an ICS.
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3.2% of ICS ‑treated patients with mild asthma 
had severe asthma exacerbation (compared with 
5.5% of those receiving placebo).25
single ‑inhaler maintenance and rescue therapy 
The availability of inhalers containing both an ICS 
and a long ‑acting β2 ‑agonist (LABA) with a rapid 
onset of action (formoterol) led to the concept of 
symptom ‑driven asthma treatment. In this treat‑
ment approach, patients are advised to use only 
one inhaler containing both an ICS and a rapid‑
‑acting LABA as maintenance (twice daily), as well 
as for as ‑needed treatment when symptoms oc‑
cur. Such an approach is sometimes referred to as 
MART (maintenance and reliever therapy). This 
approach has some advantages, including: 1) ICS 
dose is increased when symptoms are present 
and adjusted to symptom severity; 2) the inhal‑
er contains a rapid ‑acting β2 ‑agonist, so the ef‑
fect of inhalation is immediately felt by the pa‑
tient; and 3) the patient has the sense of a more 
active participation in therapy. The 2 latter ben‑
efits may potentially improve adherence to ther‑
apy, although this has not been formally studied.
The above approach to treatment has been 
studied in a number of RCTs, done mainly in pa‑
tients with moderate to severe asthma.26‑33 MART 
was more effective in terms of reducing the risk 
of exacerbations when compared with the regu‑
lar use of a higher ICS dose, or a combination of 
ICS and LABA. A reduction in the risk of exacer‑
bations was also reported in a Cochrane meta‑
‑analyses by Kew et al,34 who pooled the results 
of 4 studies comparing MART with LABA and ICS 
combination treatment (odds ratio [OR], 0.72; 
95% CI, 0.57–0.90 for events requiring hospital‑
ization or emergency department visit), and by 
Cates and Karner,35 who analyzed 8 studies which 
used the “current best practice” as the compara‑
tor (OR, 0.83; 95% CI, 0.70–0.98 for exacerba‑
tions requiring oral corticosteroid course). In both 
meta ‑analyses, MART was associated with a low‑
er total dose of ICS.34,35 Consequently, the cur‑
rent guidelines allow a maintenance and reliever 
therapy with low ‑dose ICS/formoterol as an op‑
tion in patients requiring Steps 3 to 5 treatment.6
The  approach based on symptom ‑driven 
ICS dosing has now been studied in patients 
with milder asthma. A 6 ‑month RCT showed 
that as ‑needed treatment with beclometha‑
sone (250 µg) and albuterol in a single inhal‑
er had similar effects to regular treatment with 
beclomethasone (250 µg twice daily alone or 
250 µg twice daily in a single inhaler with alb‑
uterol).36 There were nonsignificant differences 
in lung function, daytime and nighttime symp‑
tom scores, as well as rescue medication use be‑
tween the as ‑needed group and patients on reg‑
ular beclomethasone treatment (or beclometh‑
asone with albuterol). The number of exacerba‑
tions was similar in the as ‑needed and regular 
beclomethasone groups and lower compared 
with the regular beclomethasone and albuterol 
group. Another trial randomized patients with 
Data from multiple clinical trials indicate that 
ICS treatment leads to improved symptom con‑
trol and a significant reduction in the risk of ex‑
acerbations8‑11 as well as a reduction of airway in‑
flammation.12 Unfortunately, according to real ‑life 
data, asthma is uncontrolled in more than 50% 
of patients,4,13 and most of them are at risk of ex‑
acerbations.14,15 Importantly, this is also true for 
the population with mild asthma, with the high 
proportion of subjects with uncontrolled asth‑
ma and the rate of severe exacerbations report‑
ed to range from 0.12 to 0.77 per patient ‑year.16 
One of the most important reasons for discrepan‑
cy between real ‑life observations and the results 
from clinical trials is the lack of patients’ compli‑
ance with maintenance treatment.17 A population‑
‑based survey has reported that only a minority 
of patients diagnosed with asthma received ad‑
equate treatment.18 This may result from differ‑
ent socioeconomic factors, with the lack of com‑
pliance being clearly the important one, as only 
about 50% of patients are reported to adhere 
to treatment recommendations.19 According to 
pharmacy data, the amount of asthma medica‑
tion prescriptions filled was sufficient only for 
about 22% of the days of the year, and only less 
than 10% of patients continued treatment for 
longer than 1 year.20 The mean adherence rate to 
ICS treatment ranges from 22% to 63%.21 About 
one ‑fourth of asthma exacerbations may be re‑
lated to nonadherence to ICS treatment.22 Poor 
compliance has been reported in patients with 
asthma across all levels of disease severity: from 
mild to severe asthma.23,24 Moreover, some pa‑
tients use controllers when symptoms are present, 
but stop regular treatment on achieving disease 
control, which leads to clinical deterioration. Fi‑
nally, it has to be remembered still than even pa‑
tients with mild asthma adequately treated with 
ICS are at risk for severe exacerbations: in a large 
randomized clinical trial (RCT) lasting 3 years, 
TAbLE 1 Levels of intensity of asthma treatment (based on Global Initiative for 
Asthma [GINA] Guidelines, modified)6
Step Preferred regular 
(controller) treatment
Other option(s) As ‑needed 
treatment 
(reliever)
1 None Consider low ‑dose ICS SABA
2 Low ‑dose ICS LTRA SABA
3 Low ‑dose ICS/LABA Medium/high ‑dose ICS
Low ‑dose ICS + LTRA
SABA
Low ‑dose ICS/
formoterol
4 Medium/high ‑dose ICS/
LABA
Medium/high ‑dose ICS 
+ tiotropium
Medium/high ‑dose ICS 
+ LTRA
SABA
Low ‑dose ICS/
formoterol
5 Refer for specialist care, 
add tiotropium,  
anti‑IgE, anti –IL ‑5
Add low ‑dose OCS SABA
Low ‑dose ICS/
formoterol
Abbreviations: anti ‑IgE, anti –immunoglobulin E; anti–IL ‑5, anti–interleukin ‑5; ICS, 
inhaled corticosteroid; LABA, long ‑acting β2 ‑agonist; LTRA, leukotriene receptor 
antagonist; OCS, oral corticosteroid; SABA, short ‑acting β2 ‑agonist
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asthma (OR, 1.14; 95% CI, 1.00–1.30; P = 0.046) and 
significantly reduced the annual rate of severe ex‑
acerbations (rate ratio, 0.36; 95% CI, 0.27–0.49).
The comparison with regular budesonide treat‑
ment yielded similar results in both trials despite 
some differences in study designs. In SYGMA 1, 
the rates and time to the first severe and mod‑
erate to severe exacerbations were among sec‑
ondary outcomes, and they did not differ signif‑
icantly between regular ICS and as ‑needed ICS/
LABA treatment. In SYGMA 2, the annual rate of 
severe exacerbations was the primary outcome, 
and the trial was able to confirm noninferiority 
of as ‑needed ICS/LABA compared with regular 
budesonide treatment. Neither trial found a dif‑
ference in the number of severe exacerbations be‑
tween as‑needed ICS/formoterol treatment and 
regular ICS treatment (FIguRE 1).
These studies used different methods to assess 
asthma control, but in both studies as ‑needed 
budesonide/formoterol was inferior to regular 
budesonide treatment. In SYGMA 1, the number 
of weeks with well ‑controlled asthma was the pri‑
mary outcome, and control was assessed based 
on the use of as ‑needed medication, data from 
an electronic diary (including daytime symptom 
score, nighttime awakening and morning peak 
expiratory flow), and data on an additional use 
of inhaled or oral corticosteroids. In SYGMA 2, 
the percentage of reliever ‑free days and the Asth‑
ma Control Questionnaire ‑5 (ACQ ‑5) score were 
among the secondary endpoints. Compared with 
as ‑needed ICS/LABA use in patients on regu‑
lar ICS treatment, the proportion of weeks with 
well ‑controlled asthma was significantly higher 
in the SYGMA 1 trial (44.4% vs 34.4%), where‑
as in SYGMA 2, the change in ACQ ‑5 score was 
larger by 0.11 points (95% CI, 0.07–0.15). Sim‑
ilarly, in both trials, regular ICS treatment led 
to a greater increase in lung function compared 
with as ‑needed combined budesonide/formoter‑
ol treatment. On the other hand, the ICS doses 
in as ‑needed budesonide/formoterol groups were 
mild and moderate asthma to a treatment with 
an ICS inhaled each time when a rescue inhaler 
was used or to regular treatment adjusted as per 
guidelines or based on exhaled nitric oxide lev‑
els.37 The symptoms ‑based ICS dosing was simi‑
larly effective as regular ICS therapy in the 2 oth‑
er trial groups (similar time to first treatment 
failure, treatment failure rates, symptom scores, 
or exacerbation rates). In both trials, cumulative 
doses of an ICS were lower in patients allocated 
to the symptom ‑driven treatment arm.
Recent data on intermittent inhaled corticosteroid 
dosing in mild asthma Recently, the results of 
2 large double ‑blind RCTs, SYGMA 1 (Symbicort 
Given as Needed in Mild Asthma 1) and SYGMA 
2 (Symbicort Given as Needed in Mild Asthma 
2), assessing as ‑needed use of ICS/LABA in mild 
asthma, were published.38,39 The studies includ‑
ed children aged at least 12 years and adults with 
mild asthma, who had indications for regular ICS 
treatment. Each study lasted 52 weeks and includ‑
ed about 4000 participants. Approximately half 
of the patients in both trials had uncontrolled 
asthma while using only as ‑needed short ‑acting 
inhaled β2 ‑agonist (SABAs), whereas the other 
half had well ‑controlled asthma using low ‑dose 
ICS. In SYGMA 1, participants were randomized 
to one of the 3 arms: 1) the SABA (terbutaline) 
used as needed, 2) budesonide and formoterol in 
one inhaler (200 μg + 6 μg) used as needed, or 3) 
twice ‑daily budesonide (200 μg) and terbutaline 
as needed. In the first 2 arms, a matched place‑
bo was used twice daily.38 In SYGMA 2, patients 
were randomly assigned to twice ‑daily placebo 
with budesonide and formoterol inhaler (200 μg 
+ 6 μg) used as needed or twice ‑daily budesonide 
(200 μg) with terbutaline used as needed.39
In SYGMA 1, in comparison with as ‑needed ter‑
butaline treatment, as ‑needed ICS/LABA treatment 
improved symptom control and reduced exacerba‑
tion risk. As ‑needed budesonide/formoterol in‑
creased the proportion of weeks with well ‑controlled 
FIguRE 1 Proportion of  
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exacerbations in 
SYGMA 1 and SYGMA 2 
trials 
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ICS treatment resulted in better lung function 
and asthma control, although the differences ob‑
served in the trials did not exceed the clinically 
important difference for either forced expirato‑
ry volume in 1 second or ACQ ‑5.
These studies suggest that there is yet another 
therapeutic option for mild asthma, which allows 
clinicians to better tailor treatment to the indi‑
vidual patient’s needs (TAbLE 2). This new regimen 
may appeal to patients who are concerned about 
the side effects of ICS treatment (as the dose is 
much lower than in regular treatment), or to those 
who experience difficulty in following the fixed‑
‑dose regimen. On the other hand, patients will‑
ing to achieve optimal asthma control may choose 
regular ICS treatment. The art of medicine is 
the art of choice: with the new findings, we have 
yet another option to help effectively manage pa‑
tients with mild asthma.
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